

# CHARACTERISTICS OF THE GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the "Directors") of Prime Intelligence Solutions Group Limited (the "Company") collectively and individually accept full responsibility, includes particulars give in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.

#### 香港聯合交易所有限公司(「聯交所」) GEM 的特色

GEM 的定位,乃為中小型公司提供一個上市的市場,此等公司相比起其他在聯交所上市的公司帶有較高投資風險。有意投資者應瞭解投資於該等公司的潛在風險,並應經過審慎周詳考慮後方作出投資決定。

由於GEM上市公司普遍為中小型公司,在GEM買賣的證券可能會較於聯交所主板買賣的證券承受較大的市場波動風險,同時亦無法保證在GEM買賣的證券會有高流涌量的市場。

香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責,對其準確性或完整性亦不發表任何聲明,並明確表示概不就因 本報告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本報告載有根據聯交所 GEM 證券上市規則(「**GEM 上市規則**」)規定而提供有關匯安智能科技集團有限公司(「**本公司**」)的資料,本公司的董事(「董事」)願就本報告共同及個別承擔全部責任。董事作出一切合理查詢後,確認就彼等所深知及確信,本報告所載資料在所有重大方面均屬準確完整,並無誤導或欺詐成分;且本報告並無遺漏任何其他事宜,致使其所載任何陳述或本報告產生誤導。

## **Corporate Information**

## 公司資料

#### **REGISTERED OFFICE**

P.O. Box 1350 Clifton House 75 Fort Street Grand Cayman KY1-1108 Cayman Islands

# HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit A, 6/F, TLP132 Nos. 132-134 Tai Lin Pai Road Kwai Chung, New Territories Hong Kong

#### **EXECUTIVE DIRECTORS**

Mr. Yuen Kwok Wai, Tony *(Chairman and Chief Executive Officer)*Ms. Yuen Mei Ling, Pauline
Ms. Sun Ngai Chu, Danielle

#### **NON-EXECUTIVE DIRECTOR**

Mr. Yam Chiu Fan, Joseph

#### **INDEPENDENT NON-EXECUTIVE DIRECTORS**

Mr. Hui Man Ho, Ivan Mr. Chung Billy Mr. Mui Pak Kuen

#### **AUTHORISED REPRESENTATIVES**

Mr. Yuen Kwok Wai, Tony Mr. Chou Chiu Ho

#### **COMPANY SECRETARY**

Mr. Chou Chiu Ho (HKICPA, ACCA)

#### **COMPLIANCE OFFICER**

Ms. Yuen Mei Ling, Pauline

#### **AUDIT COMMITTEE**

Mr. Chung Billy *(Chairman)* Mr. Hui Man Ho, Ivan Mr. Mui Pak Kuen

#### **NOMINATION COMMITTEE**

Mr. Hui Man Ho, Ivan *(Chairman)*Mr. Chung Billy
Mr. Mui Pak Kuen

#### 註冊辦事處

P. O. Box 1350 Clifton House 75 Fort Street Grand Cayman KY1-1108 Cayman Islands

#### 香港總辦事處及主要營業地點

香港 新界葵涌 大連排道132-134號 TLP132 六樓 A 室

#### 執行董事

阮國偉先生*(主席兼行政總裁)* 阮美玲女士 孫毅珠女士

#### 非執行董事

任超凡先生

#### 獨立非執行董事

許文浩先生 鍾定縉先生 梅栢權先生

#### 授權代表

阮國偉先生 周昭何先生

#### 公司秘書

周昭何先生(HKICPA, ACCA)

#### 合規主任

阮美玲女士

#### 審核委員會

鍾定縉先生(主席) 許文浩先生 梅栢權先生

#### 提名委員會

許文浩先生(主席) 鍾定縉先生 梅栢權先生

## **Corporate Information**

## 公司資料

#### **REMUNERATION COMMITTEE**

Mr. Mui Pak Kuen (Chairman)

Mr. Chuna Billy

Mr. Hui Man Ho, Ivan

Ms. Yuen Mei Ling. Pauline

#### **LEGAL ADVISER**

As to Hong Kong law

Hastings & Co.

#### **COMPLIANCE ADVISER**

Ample Capital Limited

#### **AUDITOR**

World Link CPA Limited

5/F., Fast East Consortium Building,

121 Des Voeux Road Central,

Hong Kong

# PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS

Estera Trust (Cayman) Ltd.

P.O. Box 1350

Clifton House

75 Fort Street

Grand Cayman

KY1-1108

Cayman Islands

# HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited

Level 22, Hopewell Centre

183 Queen's Road East

Hong Kong

#### PRINCIPAL BANKER

The Hongkong and Shanghai Banking Corporation Limited

#### **WEBSITE**

www.primeintelligence.com.hk

#### **STOCK CODE**

8379

#### 薪酬委員會

梅栢權先生(主席)

鍾定縉先生

許文浩先生

阮美玲女十

#### 法律顧問

有關香港法律

希仕廷律師行

#### 合規顧問

豐盛融資有限公司

#### 核數師

華普天健(香港)會計師事務所有限公司

香港

德輔道中121號

遠東發展大廈5樓

#### 開曼群島主要股份過戶登記處

Estera Trust (Cayman) Ltd.

P.O. Box 1350

Clifton House

75 Fort Street

Grand Cayman KY1-1108

Cayman Islands

#### 香港股份過戶登記分處

卓佳證券登記有限公司

香港

皇后大道東183號

合和中心22樓

#### 主要往來銀行

香港上海滙豐銀行有限公司

#### 網址

www.primeintelligence.com.hk

#### 股份代號

8379

# Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 未經審核簡明綜合損益及其他全面收益表

The Board of Directors (the "Board") of Prime Intelligence Solutions Group Limited (the "Company") is pleased to present the unaudited condensed consolidated results of the Company and its subsidiaries (collectively referred to as the "Group") for the three and nine months ended 31 December 2018 together with the unaudited and audited comparative figures for the corresponding periods in 2017 as follows:

匯安智能科技集團有限公司(「本公司」)的董事會(「董事會」) 欣然提呈以下本公司及其附屬公司(統稱「本集團」)截至 2018年12月31日止三個月及九個月的未經審核簡明綜合業 績,連同2017年同期未經審核及經審核比較數字:

			Three months ended 31 December 截至12月31日止三個月			ember
			,		截至12月31	
			2018 2018年	2017 2017年	2018 2018年	2017 2017年
			2018 <del>+</del> HK\$'000	HK\$'000	HK\$'000	2017 <del>+</del> HK\$'000
			千港元	千港元	千港元	千港元
		Notos				
		Notes 附註	(unaudited) (未經審核)	(unaudited) (未經審核)	(unaudited) (未經審核)	(unaudited) (未經審核)
		門註	(不經番似)	(不經番似)	(不經番核)	(不經番核)
Revenue	收益	3	11,656	18,866	37,113	54,224
Cost of sales	銷售成本		(6,235)	(8,266)	(18,920)	(21,831)
Gross profit	毛利		5,421	10,600	18,193	32,393
Other income	其他收入	4	233	20	537	236
Selling and distribution costs	銷售及分銷成本		(2,140)	(1,408)	(4,890)	(3,902)
Administrative expenses	行政開支		(5,602)	(5,327)	(15,659)	(17,026)
, carrianottativo oxponoco	110000		(0,002)	(0,021)	(10,000)	(17,020)
Profit/(loss) from operation	來自經營之溢利/(虧損)		(2,088)	3,885	(1,819)	11,701
Finance costs	財務成本		(8)	(15)	(28)	(71)
Profit/(loss) before tax	除税前溢利/(虧損)		(2,096)	3,870	(1,847)	11,630
Income tax expense	所 <b>們加一門</b> 人( <b>相頂</b> ) 所得税開支	5	(65)	(710)	(364)	
income tax expense	川特忱用又	5	(00)	(7 10)	(304)	(2,652)
Profit/(loss) for the period	期內溢利/(虧損)	6	(2,161)	3,160	(2,211)	8,978
Other comprehensive income for the period, net of tax:	期內其他全面收益,扣除税項:					
Item that may be reclassified to profit or loss:	可能重新分類至損益之項目:					
Exchange differences on translating	換算海外業務時之匯兑差額					
foreign operations			4	201	(283)	434
Total comprehensive income for the period attributable	本公司擁有人應佔期內收益總額					
to the owners of the Company			(2,157)	3,361	(2,494)	9,412
(Loss)/earnings per share (cents)	每股(虧損)/盈利(仙)					
- Basic	- 基本	8	(0.27)	0.53	(0.28)	1.5
<ul><li>Diluted</li></ul>	<b>一</b> 攤薄	8	(0.27)	0.53	(0.28)	1.5

## Unaudited Condensed Consolidated Statement of Changes in Equity 未經審核簡明綜合權益變動表

		Share capital	Share premium	Merger reserve	Legal reserve	Foreign currency translation reserve 外幣換算	Retained profits	Total reserve	Total equity
		股本	股份溢價	合併儲備	法定儲備	儲備	保留溢利	總儲備	總權益
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元
Balance at 1 April 2017 (audited)	於 <b>2017</b> 年4月1日 的餘額(經審核)	_*	_	17,079	12	(688)	17,826	34,229	34,229
Total comprehensive income for the period (unaudited)	期內全面收益總額 (未經審核)	_	_	-	_	434	8,978	9,412	9,412
Balance at 31 December 2017 (unaudited)	於 <b>2017</b> 年12月31日 的餘額(未經審核)		-	17,079	12	(254)	26,804	43,641	43,641
Balance at 1 April 2018 (audited) Total comprehensive income	於2018年4月1日 的餘額(經審核) 期內全面收益總額	8,000	51,682	17,079	12	2	22,040	90,815	98,815
for the period (unaudited)	(未經審核)	-		_	-	(283)	(2,211)	(2,494)	(2,494)
Balance at 31 December 2018 (unaudited)	於 <b>2018</b> 年 <b>12</b> 月 <b>31</b> 日 的餘額(未經審核)	8,000	51,682	17,079	12	(281)	19,829	88,321	96,321

<sup>\*</sup> Represents amount less than HK\$1,000

<sup>\*</sup> 指金額少於1,000港元

#### 1. GENERAL INFORMATION

The Company was incorporated in the Cayman Islands as an exempt company with limited liability under the Companies Law (as revised) of the Cayman Islands on 16 October 2015. The address of its registered office is P.O. Box 1350, Clifton House, 75 Fort Street, Grand Cayman, KY1-1108, Cayman Islands. The address of its principal place of business is located at Unit A, 6/F TLP132, Nos. 132–134 Tai Lin Pai Road, Kwai Chung, New Territories, Hong Kong. The Company's shares are listed on GEM of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") since 14 February 2018 (the "Listing").

The Company is an investment holding company. The principal activities of its subsidiaries are sales of biometrics identification devices and other devices and accessories and provision of auxiliary and other services.

# 2. BASIS OF PRESENTATION AND PREPARATION OF FINANCIAL STATEMENTS

The unaudited condensed consolidated financial statements of the Group for the three and nine months ended 31 December 2018 are unaudited but have been reviewed by the audit committee of the Company (the "Audit Committee"). The unaudited condensed consolidated financial statements were approved for issue by the Directors on 4 February 2019. The unaudited condensed consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") which in collective term includes Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKAS") and Interpretations issued by Hong Kong Institute of Certified Public Accountants (the "HKICPA"), accounting principles generally accepted in Hong Kong and the applicable disclosure provisions of the Rules Governing the Listing of Securities on GEM of the Stock Exchange.

The unaudited condensed consolidated results have been prepared under the historical cost convention. The unaudited condensed consolidated results of the Group for the three and nine months ended 31 December 2018 do not include all the information and disclosures required in the annual financial statements of the Group and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 March 2018 (the "2018 Consolidated Financial Statements"). Except as described in paragraph headed "Change in accounting policies" below, the accounting policies and methods of computation used in the preparation of the unaudited condensed consolidated results are consistent with those used in the 2018 Consolidated Financial Statements.

The unaudited condensed consolidated financial statements of the Group are presented in Hong Kong dollars, which is the functional currency of the Company.

#### Change in Accounting Policies

In the current period, the Group has adopted all the new and revised HKFRSs issued by the HKICPA that are relevant to its operation and effective for its accounting period beginning on 1 April 2018. The Group has initially adopted HKFRS 9 "Financial Instruments" and HKFRS 15 "Revenue from Contracts with Customers" from 1 April 2018. The Group has not early applied the new and revised HKFRSs that have been issued by the HKICPA but are yet to be effective.

#### 1. 一般資料

本公司於2015年10月16日根據開曼群島公司法(經修訂)在開曼群島註冊成立及註冊為獲豁免有限公司。其註冊辦事處地址為P.O. Box 1350, Clifton House, 75 Fort Street, Grand Cayman, KY1-1108, Cayman Islands。其主要營業地點的地址位於香港新界葵涌大連排道132-134號TLP132六樓A室。本公司股份已自2018年2月14日起在香港聯合交易所有限公司(「聯交所」) GEM 上市(「上市」)。

本公司為一間投資控股公司。本公司附屬公司的主要 業務為銷售生物特徵識別裝置、其他裝置及配件以及 提供配套及其他服務。

#### 2. 財務報表的呈報及編製基準

本集團截至2018年12月31日止三個月及九個月之未經審核簡明綜合財務報表為未經審核,但已由本公司審核委員會(「審核委員會」)審閱。董事於2019年2月4日批准刊發未經審核簡明綜合財務報表。未經審核簡明綜合財務報表已遵照香港會計師公會(「香港會計師公會」)頒佈的香港財務報告準則(「香港財務報告準則」)(此綜合詞彙包括:香港財務報告準則、香港會計準則「「香港會計準則」)及詮釋)、香港公認會計原則及聯交所GEM的證券上市規則之適用披露規定條文編製。

未經審核簡明綜合業績已按歷史成本法編製。本集團截至2018年12月31日止三個月及九個月的未經審核簡明綜合業績並不包括本集團年度財務報表所有所須資料及披露,並應與本集團截至2018年3月31日止年度綜合財務報表(「2018綜合財務報表」)一併閱讀。除「會計政策的變更」一節所載外,編製未經審核簡明綜合業績所用會計政策及計算方法與2018綜合財務報表所用者貫徹一致。

本集團的未經審核簡明綜合財務報表以港元呈列,港 元為本公司之功能貨幣。

#### 會計政策變動

於本期間,本集團已採納所有新訂及經修訂香港財務報告準則,由香港會計師公會頒佈之與其業務有關及於2018年4月1日起開始的會計期間生效。本集團已自2018年4月1日起首次採納香港財務報告準則第9號「金融工具」及香港財務報告準則第15號「來自客戶合約之收益」。本集團未就香港會計師公會頒佈而未生效的新香港財務準則及其修訂本作提早應用。

# 2. BASIS OF PRESENTATION AND PREPARATION OF FINANCIAL STATEMENTS (continued)

#### **Change in Accounting Policies**

HKFRS 9 — Financial Instruments

The Group has applied HKFRS 9 "Financial Instruments" on 1 April 2018. HKFRS 9 introduces new requirements for the classification and measurement of financial assets. HKFRS 9 includes a new expected loss impairment model for all financial assets not measured at fair value through profit or loss ("FVTPL") replacing the incurred loss model in HKAS 39 and new general hedge accounting requirements to allow entities to better reflect their risk management activities in financial statements. HKFRS 9 carries forward the recognition, classification and measurement requirements for financial liabilities from HKAS 39, except for financial liabilities designated at FVTPL, where the amount of change in fair value attributable to change in credit risk of the liability is recognised in other comprehensive income unless that would create or enlarge an accounting mismatch. In addition, HKFRS 9 retains the requirements in HKAS 39 for derecognition of financial assets and financial liabilities. Under HKFRS 9, it is no longer necessary for a loss event to occur before an impairment loss is recognized.

The application of the expected credit loss model of HKFRS 9 might result in earlier provision of credit losses in relation to the Group's trade receivables measured at amortised cost. However, the adoption of HKFRS 9 has no material effect on the Group's unaudited condensed consolidated financial statements as the credit quality of the financial assets of the Group does not change significantly for the nine months ended 31 December 2018.

#### HKFRS 15 — Revenue from Contracts with Customers

The Group has applied HKFRS 15 "Revenue from Contracts with Customers" on 1 April 2018. This new standard establishes a single revenue recognition framework. The core principle of the framework is that an entity should recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. HKFRS 15 has superseded existing revenue recognition guidance including HKAS 18 Revenue, HKAS 11 Construction Contracts and related interpretations. As a result, the Group has changed its accounting policy in the unaudited condensed consolidated financial statements for revenue recognition as detailed below.

The Group elects to use the modified retrospective approach which means that the cumulative effect of the adoption of HKFRS 15 will be recognised in retained earnings as of 1 April 2018 and that comparatives will not be restated.

#### 2. 財務報表的呈報及編製基準(續)

#### 會計政策的變更

香港財務報告準則第9號 一「金融工具」

本集團已於2018年4月1日應用香港財務報告準則第9號「金融工具」。香港財務報告準則第9號引入新的金融資產的分類及計量規定。香港財務報告準則第9號引入針對所有按公平值確認損益(「FVTPL」)之金融資本的新預期虧損減值模型來代替香港會計準則第9號內的已發生虧損減值模型,以及新的一般對沖會計要求,以容許實體更能夠反映其財務表的風險管理活動。香港財務報告準則第9號保留香港會計準則第39號內的財務負債確認、分類及計量,除財務負債以FVTPL取決時,歸因於信貸風險變化的公平值變動的金額在其他全面收益內確認,除非這會產生或加劇會計錯配,則作別論。此外,香港財務報告準則第9號保留香港財務報告準則第39號對終止確認金融資產及財務負債的要求。根據香港財務報告準則第9號,減值虧損毋須按虧損事件進行確認。

香港財務報告準則第9號的預期信貸虧損模型的應用可能導致相關的信貸虧損作提前撥備,信貸虧損乃是於本集團以攤銷成本計量的應收貿易金額。然而,截至2018年12月31日止九個月內,由於本集團的金融資產信貸質素未有重大改變,採納香港財務報告準則第9號未必對就本集團未經審核簡明綜合財務報表造成其他重大影響。

香港財務報告準則第15號一「來自客戶合約收益」本集團已於2018年4月1日應用香港財務報告準則第15號「來自客戶合約收益」。新標準確立單一收益確認框架。該框架的核心原則為,一個實體所確認之收益為對客戶轉移貨品或服務之描述,有關金額反映實體預期因交換該等貨品及服務而有權取得的代價。香港財務報告準則第15號已取代所有現有收益確認指引,包括香港會計準則第18號收益、香港會計準則第11號「建築合約」及相關詮釋。因此,為本集團就未經審核簡明綜合財務報表的收益確認已變更其會計政策,有關詳情如下。

本集團擬採用經修改追溯性方法採納準則,意味著採納的累加影響將於2018年4月1日的保留盈利內確認 且比較數字將不予重列。

# 2. BASIS OF PRESENTATION AND PREPARATION OF FINANCIAL STATEMENTS (continued)

#### Change in Accounting Policies (continued)

HKFRS 15 — Revenue from Contracts with Customers (continued) Under HKFRS 15, the Group recognises the revenue from provision of auxiliary and other services when the performance obligation is satisfied over time and measures the progress towards complete satisfaction in accordance with the output method while the customer obtains control of the promised good or service in the contract.

The adoption of HKFRS 15 has no material effect on the adjustments to the opening balance of the retained earnings at 1 April 2018 in the unaudited condensed consolidated statement of changes in equity and the amounts recognised in the unaudited condensed consolidated statement of profit or loss and other comprehensive income.

#### 3. REVENUE

Revenue represents the invoiced values of goods sold and services rendered, after allowances for returns and discounts during the reporting periods.

#### 2. 財務報表的呈報及編製基準(續)

#### 會計政策的變更(續)

香港財務報告準則第15號 一「來自客戶合約收益」(續) 根據香港財務報告準則第15號,來自提供配套及其 他服務的收益隨履約義務達成的時間確認,以及根據 出產方法計量將邁向完全滿意及客戶掌控該等合約訂 明的貨品或服務的進程。

採納香港財務報告準則第15號不會對截至2018年4 月1日未經審核簡明綜合權益變動表的年初保留盈利 結餘調整,以及未經審核簡明綜合損益表及其他全面 收益表確認的金額作出重大影響。

#### 3. 收益

收益指所售貨品及提供服務的發票值,其於報告期內 經扣除退貨及折扣後的發票值。

		nths ended cember I 日止三個月	Nine months ended 31 December 截至12月31日止九個月	
	<b>2018</b> 2017		2018	2017
	2018年	<b>2018年</b> 2017年 <b>HK\$'000</b> HK\$'000		2017年
	HK\$'000			HK\$'000
	千港元	<b>千港元</b> 千港元		千港元
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	(未經審核)	(未經審核)	(未經審核)	(未經審核)
Sales of biometrics identification devices, 銷售生物特徵識別裝置、 security products and other accessories 保安產品及其他配件	7,939	13,064	25,454	36,542
Provision of auxiliary and other services 提供配套及其他服務	3,717	5,802	11,659	17,682
	11,656	18,866	37,113	54,224

#### 4. OTHER INCOME

#### 4. 其他收入

			nths ended eember I 日止三個月	Nine months ended 31 December 截至12月31日止九個月	
		2018年 HK\$'000 千港元 (unaudited) (未經審核)	2017 2017年 HK\$'000 千港元 (unaudited) (未經審核)	2018年 HK\$'000 千港元 (unaudited) (未經審核)	2017 2017年 HK\$'000 千港元 (unaudited) (未經審核)
Interest income Gain on disposals of property, plant and equipment Others	利息收入 出售物業、廠房及設備收益 其他	202	1 1 1 18	482 20 35	3 211 22
	XII	233	20	537	236

#### 5. INCOME TAX EXPENSE

#### 5. 所得税開支

		31 Dec	Three months ended 31 December 截至12月31日止三個月		ths ended ember l 日止九個月
		2018年 HK\$'000 千港元 (unaudited) (未經審核)	2017 2017年 HK\$'000 千港元 (unaudited) (未經審核)	2018年 2018年 HK\$'000 千港元 (unaudited) (未經審核)	2017 2017年 HK\$'000 千港元 (unaudited) (未經審核)
Provision for the period: Hong Kong Profits Tax Macao Complementary Tax	期內撥備: 香港利得税 澳門所得補充税	65 - 65	635 75 710	364 - 364	2,486 166 2,652

Hong Kong Profits Tax is provided at 16.5% (three and nine months ended 31 December 2017: 16.5%) based on the estimated assessable profits arising in or derived from Hong Kong.

On 21 March 2018, the Inland Revenue (Amendment) (No. 7) Bill 2017 (the "Tax Amendment"), which introduces a two-tiered profits tax regime, was substantively enacted. Under the two-tiered profits tax regime, the first HK\$2 million of assessable profits of qualifying corporations will be taxed at 8.25% with effect from the year assessment 2018/2019. Profits above HK\$2 million will continue to be subject to the tax rate of 16.5%. The two-tiered profits tax regime is only applicable to one of the Group's HK subsidiary under the "Connected Entities" concept as stipulated in the Tax Amendment.

香港利得税已就於香港產生的估計應課税溢利按税率 16.5%(截至2017年12月31日止三個月及九個月: 16.5%)計提撥備。

於2018年3月21日,引入兩級制利得稅制度的2017年稅務(修訂)(第7號)條例草案(「稅務修訂」)被實質性立法。根據兩級制利得稅制度,合資格實體的首2百萬港元應課稅溢利將自2018/2019評估年度起以8.25%的稅率徵稅。超過2百萬港元之溢利將以16.5%的稅率徵稅。該如稅務修訂所訂明的「關連實體」的概念所規定,兩級制利得稅制度僅適用於本集團的其中一個香港附屬公司。

#### 5. INCOME TAX EXPENSE (continued)

For the Group's subsidiary established and operated in the PRC is subject to PRC Enterprise Income Tax at the rate of 25.0% (three and nine months ended 31 December 2017: 25.0%). No PRC Enterprise Income Tax has been provided for the three and nine months ended 31 December 2018 (three and nine months ended 31 December 2018 (three and nine months ended 31 December 2017: Nil) as the Group's PRC subsidiary either did not generate any assessable profits or has sufficient tax losses brought forward to offset against its assessable profits generated during the reporting periods.

For the Group's subsidiary established and operated in Macau is subject to Macao Complementary Tax, under which taxable income of up to MOP600,000 is exempted from taxation with taxable income beyond this amount to be taxed at the rate of 12.0% for the three and nine months ended 31 December 2017. For the three and nine months ended 31 December 2018, Macao Complementary Tax has been provided at the rate of 12.0% on the estimated taxable income of the Group's Macau subsidiary.

#### 6. PROFIT/(LOSS) FOR THE PERIOD

#### 5. 所得税開支(續)

本集團在中國成立及經營的附屬公司須按税率25.0%(截至2017年12月31日止三個月及九個月:25.0%)繳納中國企業所得稅。截至2018年12月31日止三個月及九個月內概無計提中國企業所得稅(截至2017年12月31日止三個月及九個月:無),乃因為本集團的中國附屬公司於報告期內並無產生任何應課稅溢利或結轉稅項虧損足以抵銷其應課稅溢利。

本集團在澳門成立及經營的附屬公司須繳納澳門所得補充税,截至2017年12月31日止三個月及九個月應課税收入最高600,000澳門幣豁免納税,超出該金額的應課税收入按12.0%的税率納税。截至2018年12月31日止三個月及九個月,澳門所得補充稅已就本集團澳門附屬公司的估計應課税收入按税率12.0%計提。

#### 6. 期內溢利/(虧損)

		Three months ended 31 December 截至12月31日止三個月		Nine months ended 31 December 截至12月31日止九個	
		<b>2018</b> 2017		2018	2017
		2018年	2017年	2018年	2017年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Depreciation of property, plant and equipment Staff costs (including Directors' emoluments)	物業、廠房及設備折舊 員工成本(包括董事酬金)	233	143	738	441
<ul> <li>Salaries, bonus, allowances and</li> </ul>	一 薪金、花紅、津貼及				
other benefits in kind	其他實物利益	8,542	4,334	15,676	12,892
<ul><li>Commission</li></ul>	<b>一</b> 佣金	158	77	543	926
Retirement benefits scheme contributions	一 退休福利計劃供款	379	272	873	778
	0.7.4.8.1	9,079	4,683	17,092	14,596
Cost of inventories sold	已售存貨成本	4,512	6,613	14,019	17,228
Foreign exchange losses, net	匯	31	42	173	68
Gain/(loss) on disposals of property,	出售物業、廠房及設備收益/				
plant and equipment	(虧損)	-	(1)	20	(211)
Listing expenses	上市開支	-	1,114	-	4,913
Auditor's remuneration	核數師酬金	125	125	399	375

#### 7. DIVIDEND

No dividend was declared or paid during the three and nine months ended 31 December 2018 (three and nine months ended 31 December 2017: Nil).

#### 7 股 自

本公司並無於截至2018年12月31日止三個月及九個月宣派或派付股息(截至2017年12月31日止三個月及九個月:無)。

#### 8. (LOSS)/EARNINGS PER SHARE

#### (a) Basic (loss)/earnings per share

The calculation of the basic (loss)/earnings per share is based on the following:

#### 8. 每股(虧損)/盈利

#### (a) 每股基本(虧損)/盈利

每股基本(虧損)/盈利乃基於以下數據計算:

		Three months ended 31 December		Nine months ended 31 December	
		截至12月31	1日止三個月	截至12月31	I日止九個月
		2018	2017	2018	2017
		2018年	2017年	2018年	2017年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
(Loss)/earnings for the purpose of calculating basic (loss)/earnings per share	就計算每股基本 (虧損)/盈利的(虧損)/盈利	(2,161)	3,160	(2,211)	8,978
Number of shares	股份數目				
Weighted average number of ordinary shares for the purpose of calculating	就計算每股基本(虧損)/盈利 的普通股加權平均數(附註)				
basic (loss)/earnings per share (note)		800,000,000	600,000,000	800,000,000	600,000,000

Note: The weighted average number of ordinary shares in issue during the three and nine months ended 31 December 2017 was calculated based on the assumption that 600,000,000 ordinary shares, being the number of shares in issue immediately after the completion of share capitalisation on 18 January 2018, deemed to have been issued. Details of the share capitalisation issue are set out in note 29(b) to the 2018 Consolidated Financial Statements.

#### (b) Diluted (loss)/earnings per share

No diluted earnings per share to be presented as the Company did not have any dilutive potential ordinary shares outstanding during the three and nine months ended 31 December 2018 and 2017.

附註: 截至2017年12月31日止三個月及九個月內發行的普通股加權平均數,以假設600,000,000,000股普通股(即緊隨2018年1月18日資本化完成後的已發行股份數目)被視為已發行計算。有關股份資本化發行的詳情已載列於2018綜合財務表的附註29(b)。

#### (b) 每股攤薄(虧損)/盈利

並無可呈列的每股攤薄盈利,乃因本公司於截至2018年及2017年12月31日止三個月及九個月並無任何流通在外的潛在可攤薄普通股。

## 管理層討論及分析

#### **OVERVIEW**

The Group is a provider of biometrics identification solutions in Hong Kong, Macau and the PRC. The Group derives revenue from the following business activities: (i) sales of products which include biometrics identification devices, and other devices and accessories; and (ii) provision of auxiliary and other services. The Group's biometrics identification devices have one or more of the following functions: (i) face identification; (ii) fingerprint identification; (iii) finger vein identification (iv) hand geometry identification; and (v) iris identification. The revenue of the Group for the nine months ended 31 December 2018 was approximately HK\$37.1 million, representing a decrease of approximately 31.5% from approximately HK\$54.2 million for the nine months ended 31 December 2017. The decrease in revenue was mainly because the decrease in sales of biometrics identification devices and other accessories, in particular, the handheld devices as compared with the corresponding period in 2017.

Revenue represents the invoiced values of goods sold and services rendered, after allowances for returns and discounts during the reporting periods.

#### 概覽

本集團為香港、澳門及中國的生物特徵識別解決方案供應商。本集團透過以下業務活動產生收益:()產品銷售包括生物特徵識別裝置以及其他裝置及配件;及(i)提供配套及其他服務。本集團的生物特徵識別裝置有一個或以上的以下功能:(i)人臉識別:(ii)指紋識別:(iii)指靜脈識別:(iv)掌形識別:及(v)虹膜識別。截至2018年12月31日止九個月,本集團的收益約為37.1百萬港元、較截至2017年12月31日止九個月約54.2百萬港元減少約31.5%。收益減少主要由於生物特徵識別裝置及其他配件(尤其是手提裝置)的銷售較2017年同期減少。

收益指所售貨品及提供服務的發票值,其於報告期內經扣除 退貨及折扣後的發票值。

	31 Dec	nths ended cember I 日止三個月	Nine months ended 31 December 截至12月31日止九個月	
	<b>2018</b> 2017		2018	2017
	2018年	2017年	2018年	2017年
	HK\$'000	HK\$'000	HK\$'000	HK\$'000
	千港元	千港元	千港元	千港元
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	(未經審核)	(未經審核)	(未經審核)	(未經審核)
Sales of biometrics identification devices, 銷售生物特徵識別裝置、保安產品及				
security products and other accessories 其他配件	7,939	13,064	25,454	36,542
Provision of auxiliary and other services 提供配套及其他服務	3,717	5,802	11,659	17,682
	11,656	18,866	37,113	54,224

#### Cost of Sales and Gross Profit

The majority of the Group's cost of sales was costs of inventories sold. The Group's costs of inventories sold decreased by approximately 18.6% to approximately HK\$14.0 million for the nine months ended 31 December 2018 as compared to the same period last year. The gross profit margin dropped from approximately 59.7% for the nine months ended 31 December 2017 to approximately 49.0% for the nine months ended 31 December 2018. The gross profit also dropped from approximately HK\$32.4 million for the nine months ended 31 December 2017 to approximately HK\$18.2 million for the nine months ended 31 December 2018. The decrease of gross profit margin and gross profit was mainly due to the decrease of gross profit of handheld devices.

#### 銷售成本及毛利

本集團大部份銷售成本為已售存貨成本。截至2018年12月31日止九個月·本集團的已售存貨成本較去年同期減少約18.6%至約14.0百萬港元。毛利率由截至2017年12月31日止九個月約59.7%減少至截至2018年12月31日止九個月約49.0%。毛利由截至2017年12月31日止九個月約32.4百萬港元減至截至2018年12月31日止九個月約18.2百萬港元。毛利率及毛利的減少主要由於手提裝置的毛利降低。

## 管理層討論及分析

#### **Expenses**

Staff costs for the nine months ended 31 December 2018 were approximately HK\$17.1 million (nine months ended 31 December 2017: approximately HK\$14.6 million), representing an increase of approximately HK\$2.5 million as compared with that of last corresponding period, which was mainly due to the increase in average bonus and allowances during the period.

Administrative expenses for the nine months ended 31 December 2018 was approximately HK\$15.7 million (nine months ended 31 December 2017: approximately HK\$17.0 million), representing a decrease of approximately HK\$1.3 million as compared with the last corresponding period, which was mainly due to the net effect of increase in staff cost and decrease in listing expenses.

#### Loss for the Period

The Group incurred a net loss of approximately HK\$2.2 million for the nine months ended 31 December 2018, as compared with a net profit of approximately HK\$9.0 million for the nine months ended 31 December 2017. The decrease of net profit was mainly due to the decrease of over 25% in revenue generated from the sales of biometrics identification devices and other accessories, in particular, the handheld devices as compared with the corresponding period in 2017.

The Board does not recommend the payment of dividends for the nine months ended 31 December 2018.

#### Outlook

The ordinary shares of HK\$0.01 each (the "Shares") of the Company have been successfully listed on GEM on 14 February 2018. The Board considers that such public listing status will allow the Company to gain access to the capital market for corporate finance exercise, assist the Company in the future business development, enhance the Group's corporate profile and recognition and strengthen the Group's competitiveness.

Looking forward, the Group plans to generate further growth in existing business by strengthening its marketing capabilities and expanding its product portfolio through enhancing software development, with a view to further enlarging its market share in Hong Kong and Macau and becoming one of the active biometrics identification solutions providers in the PRC. As such, the Group plans to utilise the net proceeds from the Listing by way of share offer pursuant to the Prospectus on (i) launching of affordable locally manufactured fingerprint identification devices as part of the expansion plan of the business in Southern China; (ii) enhancing the quality of after-sale services and strengthening of the operation support as part of the expansion plan of the business in Southern China; (iii) improving its information technology system; and (iv) setting up a new and separate software development center in the PRC to further enhance and develop the Group's software.

#### 開支

截至2018年12月31日止九個月,員工成本約為17.1百萬港元(截至2017年12月31日止九個月:約14.6百萬港元),較去年同期增加約2.5百萬港元,主要由於期內平均花紅及津貼增加。

截至2018年12月31日止九個月,行政開支約為15.7百萬港元(截至2017年12月31日止九個月:約17.0百萬港元),較去年同期減少約1.3百萬港元,主要由於員工成本增加及上市開支減少的淨影響所致。

#### 期內虧損

截至2018年12月31日止九個月,本集團產生淨虧損約2.2 百萬港元,而截至2017年12月31日止九個月則產生純利約9.0百萬港元。純利減少主要由於生物特徵識別裝置及其他配件(尤其是手提裝置)的銷售所得收益較2017年同期減少逾25%。

董事會不建議就截至2018年12月31日止九個月派付股息。

#### 展望

本公司每股0.01港元的普通股(「**股份**」)已於2018年2月14日在GEM成功上市。董事會認為,上市地位將讓本公司利用資本市場進行企業融資,有助本公司的未來業務發展、提升本集團的企業形象及認受性以及加強本集團的競爭力。

展望將來,本集團計劃透過加強其營銷能力及加強軟件開發擴大其產品組合,進一步發展其現有業務,旨在進一步擴大於香港及澳門的市場佔有率及成為活躍的中國生物特徵識別解決方案供應商之一。因此,本集團計劃根據招股章程以股份發售方式動用上市所得款項淨額,以(i)推出本地製造可負擔指紋識別裝置,作為拓展華南地區業務的一部分;(ii)提高售後服務的質量及加強營運支援,作為拓展華南地區業務的一部分;(iii)改進其資訊科技系統;及(iv)於中國設立一個新的獨立軟件開發中心以進一步提升及開發本集團的軟件。

## 管理層討論及分析

# DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY ASSOCIATED CORPORATION

As at 31 December 2018, the interests and short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")), which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions in which they were taken or deemed to have under such provisions of the SFO) or which were required pursuant to Section 352 of the SFO to be entered in the register referred to therein, or which were required to be notified to the Company and the Stock Exchange pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules were as follows:

董事及最高行政人員於本公司及任何關聯法團的股份、相關股份及債權證的權益及淡倉

於2018年12月31日,本公司董事及最高行政人員於本公司或其任何相聯法團(定義見證券及期貨條例(「證券及期貨條例」)第XV部)的股份、相關股份及債券中,擁有根據證券及期貨條例第XV部第7及第8分部須知會本公司及聯交所的任何其他權益或淡倉(包括彼等根據證券及期貨條例有關條文被認為或視作擁有的權益或淡倉),或根據證券及期貨條例第352條須記錄在該條文所述登記冊內的任何其他權益或淡倉,或根據GEM上市規則第5.46至5.67條須知會本公司及聯交所的權益及淡倉如下:

#### Long positions

Ordinary share of the Company

#### 好倉

附註:

本公司普通股

Name	Capacity and nature of interest	Number of shares (note 1)	Percentage of the Company's issued share capital
名稱	身份及權益性質	<b>股份數目</b> (附註1)	佔本公司已發行 股本之百分比
Mr. Yuen Kwok Wai, Tony (" <b>Mr. Tony Yuen</b> ") (note 2)	Interest of controlled corporation	366,000,000 (L)	45.75%
阮國偉先生(「 <b>阮國偉先生</b> 」) <i>(附註2)</i>	受控制法團權益		
Ms. Yuen Mei Ling, Pauline (" <b>Ms. Pauline Yuen</b> ") (note 2)	Interest of controlled corporation	366,000,000 (L)	45.75%
阮美玲女士(「 <b>阮美玲女士</b> 」)( <i>附註2</i> )	受控制法團權益		

Note.

- The letter "L" denotes a long position in the shareholder's interest in the share capital of the Company.
- Delighting View Global Limited ("Delighting View") directly holds 366,000,000 Shares. As Delighting View is beneficially owned as to 85% and 15% by Mr. Tony Yuen and Ms. Pauline Yuen respectively and Mr. Tony Yuen and Ms. Pauline Yuen are parties acting in concert, each of Mr. Tony Yuen and Ms. Pauline Yuen is deemed to be interested in all the Share held by Delighting View under the SFO.

. 英文字母「L」表示股東於本公司股本的好倉。

 Delighting View Global Limited (「Delighting View」)直接持有 366,000,000股股份。由於Delighting View分別由阮國偉先生 及阮美玲女士實益擁有85%及15%,且阮國偉先生及阮美玲 女士為一致行動人士,故根據證券及期貨條例,阮國偉先生 及阮美玲女士各自被視為於Delighting View所持有的所有股份中擁有權益。

Save as disclosed above, as at 31 December 2018, none of the Directors and chief executive of the Company or their associates (as defined in the GEM Listing Rules) had any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 ad 8 of Part XV of the SFO (including interests or short positions which each of them has taken or deemed to be taken under the provisions of the SFO); or which were required, pursuant to Section 352 of the SFO, to be entered into the register referred to therein; or which were required, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules to be notified to the Company and the Stock Exchange.

除上文所披露者外,於2018年12月31日,概無本公司董事及最高行政人員或彼等之聯繫人(定義見GEM上市規則)於本公司或其任何相聯法團(定義見證券及期貨條例第XV部)的股份、相關股份及債券中,擁有任何根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所的權益及淡倉(包括根據證券及期貨條例有關條文彼等各自被當作或視為擁有的權益或淡倉),或根據證券及期貨條例第352條須記錄於該條例所指登記冊內的權益及淡倉,或根據 GEM上市規則第5.46至5.67條須知會本公司及聯交所的權益及淡倉。

## 管理層討論及分析

# SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS AND SHORT POSITIONS IN THE SHARES AND UNDERLYING SHARES OF THE COMPANY

As at 31 December 2018, so far as is known to the Directors, the following persons, not being Directors or chief executive of the Company had, or were deemed to have, interests or short position in the shares or underlying shares which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO; or which were recorded in the register required to be kept by the Company under Section 336 of the SFO; or who is directly or indirectly, to be interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company:

# 主要股東及其他人士於本公司股份及相關股份的權益及淡倉

於2018年12月31日,據董事所知悉,下列人士(並非本公司董事或最高行政人員)於股份或相關股份中擁有或被視為擁有根據證券及期貨條例第XV部第2及3分部條文須向本公司披露的權益或淡倉;或記錄於本公司根據證券及期貨條例第336條須存置的登記冊的權益或淡倉;或直接或間接擁有附帶權利於任何情況下均可在本公司的股東大會上投票的任何類別股本面值5%或以上權益:

#### Long positions

Ordinary shares of the Company

#### 好倉

本公司普通股

Name	Capacity and nature of interest	Number of shares (note 1)	Percentage of the Company's issued share capital
名稱	身份及權益性質	<b>股份數目</b> (附註1)	佔本公司已發行 股本之百分比
Delighting View (note 2) Delighting View (附註2)	Beneficial owner 實益擁有人	366,000,000 (L)	45.75%
Super Arena Limited ("Super Arena") (note 3) Super Arena Limited (「Super Arena」)(附註3)	Beneficial owner 實益擁有人	100,000,000 (L)	12.5%
Mr. Kor Sing Mung, Michael (" <b>Mr. Kor</b> ") <i>(note 3)</i> Kor Sing Mung, Michael 先生(「 <b>Kor 先生</b> 」) <i>(附註3)</i>	Interest of controlled corporation 受控制法團權益	100,000,000 (L)	12.5%

#### Notes:

- The letter "L" denotes a long position in the shareholder's interest in the share capital of the Company.
- 2. As Delighting View is beneficially owned as to 85% and 15% by Mr. Tony Yuen and Ms. Pauline Yuen respectively and Mr. Tony Yuen and Ms. Pauline Yuen are parties acting in concert, each of Mr. Tony Yuen and Ms. Pauline Yuen is deemed to be interested in all the Shares held by Delighting View under the SFO.
- 3. Super Arena directly holds 100,000,000 Shares. As Super Arena is beneficially owned as to 70% by Mr. Kor, Mr. Kor is deemed to be interested in all the Shares held by Super Arena under the SFO.

Save as disclosed above, as at 31 December 2018, the Directors are not aware of any other person, other than Directors and the chief executive of the Company who had, or was deemed to have, interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or, which were recorded in the register required to be kept by the Company under Section 336 of the SFO; or who is directly or indirectly, to be interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company or options in respect of such share capital.

#### 附註:

- 1. 英文字母「L」表示股東於本公司股本權益的好倉。
- 2. 由於Delighting View分別由阮國偉先生及阮美玲女士實益擁有85%及15%,且阮國偉先生及阮美玲女士為一致行動人士,故根據證券及期貨條例阮國偉先生及阮美玲女士各自被視為於Delighting View所持有的所有股份中擁有權益。
- 3. Super Arena 直接持有100,000,000 股股份。由於Super Arena 由Kor先生實益擁有70%,故根據證券及期貨條例Kor先生被 視為於Super Arena 所持有的所有股份中擁有權益。

除上文披露者外,於2018年12月31日,董事並不知悉任何 其他人士(本公司董事及最高行政人員除外)於本公司股份 或相關股份中擁有或被視為擁有根據證券及期貨條例第XV 部第2及3分部條文須向本公司披露的權益或淡倉;或記錄 於本公司根據證券及期貨條例第336條須存置的登記冊的權 益或淡倉;或直接或間接擁有附帶權利於任何情況下均可在 本公司的股東大會上投票的任何類別股本面值5%或以上權 益或有關該股本的購股權。

### 管理層討論及分析

# PURCHASES, SALES OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the nine months ended 31 December 2018.

#### **Competing Adviser's Interests**

As at the date of this report, save and except for (i) the participation of Ample Capital Limited (the "Compliance Adviser") as the sponsor and Ample Orient Capital Limited as one of the underwriters and joint lead managers in relation to the Listing; and (ii) the compliance adviser's agreement entered into between the Company and the Compliance Adviser dated 25 January 2018, neither the Compliance Adviser, nor any of its directors, employees or close associates (as defined in the GEM Listing Rules) had any interests in the securities of the Company or any other companies of the Group (including options or rights to subscribe for such securities) which is required to be notified to the Company pursuant to rule 6A.32 of the GEM Listing Rules.

#### **Competing Interests**

The Directors confirm that as at 31 December 2018, none of the Directors, the controlling shareholders of the Company and their respective associates (as defined in the GEM Listing Rules) had any interest in any business which competes or is likely to compete, directly or indirectly, with the business of the Group or any other conflicts of interest with the Group.

# COMPLIANCE WITH THE REQUIRED STANDARD OF DEALINGS IN SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the required standard of dealings (the "Required Standard of Dealings") as the code for securities transactions by the Directors on the guidelines as set out in Rules 5.48 to 5.67 of the GEM Listing Rules. Further, the Company had made specific enquiry with all Directors and each of them has confirmed his/her compliance with the Required Standard of Dealings since the Listing up to the date of this report.

#### CORPORATE GOVERNANCE PRACTICES

The Company endeavours to maintain high standard of corporate governance for the enhancement of shareholders' value and provide transparency, accountability and independence. Except for the deviation from code provision A.2.1, the Company had complied with the required code provisions set out in the Corporate Governance Code contained in Appendix 15 of the GEM Listing Rules (the "CG Code") since the Listing and up to the date of this announcement.

Code provision A.2.1 of the CG Code stipulates that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Mr. Tony Yuen is the chairman and the chief executive officer of the Company. In view of Mr. Tony Yuen is one of the founders of the Group and has been operating and managing the Group since June 1999, the Board believes that it is in the best interest of the Group to have Mr. Tony Yuen taking up both roles for effective management and business development. Therefore the Board considers that the deviation from the code provision A.2.1 of the CG Code is appropriate in such circumstances.

#### 購買、出售或贖回本公司上市證券

本公司或任何附屬公司截至2018年12月31日止九個月內, 概無購買、銷售或贖回任何本公司上市證券。

#### 合規顧問權益

於本報告日期,除(i)豐盛融資有限公司(「合規顧問」,作為保薦人)及豐盛東方資本有限公司(作為包銷商及聯席牽頭經辦人)參與上市:及(i)本公司與合規顧問訂立日期為2018年1月25日的合規顧問協議外,合規顧問或其任何董事、僱員或緊密聯繫人(定義見GEM上市規則)並無於本公司或本集團任何其他公司的證券擁有任何須根據GEM上市規則第6A.32條須知會本公司的權益(包括購股權或認購有關證券的權利)。

#### 競爭權益

董事確認,於2018年12月31日,概無董事、本公司控股股東及彼等各自的聯繫人士(定義見GEM上市規則)於與本集團業務直接或間接構成競爭或可能構成競爭的任何業務中擁有任何權益或與本集團有其他利益衝突。

#### 遵守董事進行證券交易的規定準則

本公司已採納GEM上市規則第5.48至第5.67條所載交易規定標準(「交易規定準則」),作為規管董事進行證券交易的守則。再者,本公司已向全體董事作出具體查詢,而彼等各自已確認,自上市起直至本報告日期,彼已遵守交易規定準則。

#### 企業管治常規

本公司致力維持高水準企業管治以提高股東價值,並提供透明度、問責性及獨立性。除偏離守則條文第A.2.1條外,本公司自上市起及至本公佈日期已遵守GEM上市規則附錄十五所載企業管治守則(「企業管治守則」)所載規定守則條文。

企業管治守則條文第A.2.1條規定,主席與行政總裁的角色應予區分且不應由同一人士擔任。阮國偉先生為本公司主席兼行政總裁。鑒於阮國偉先生為本集團創辦人之一且自1999年6月起一直營運及管理本集團,董事會認為就有效管理及業務發展而言,由阮國偉先生同時出任兩個職位合乎本集團的最佳利益。因此,董事會認為在有關情況下偏離企業管治守則條文第A.2.1條實屬恰當。

## 管理層討論及分析

#### **AUDIT COMMITTEE**

The Company has established the Audit Committee with written terms of reference in compliance with rules 5.28 and 5.29 of the GEM Listing Rules and code provisions C.3.3 and C.3.7 of the CG Code. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal control systems of the Group. The Audit Committee comprises three independent non-executive Directors, namely Mr. Chung Billy (chairman of the Audit Committee), Mr. Hui Man Ho, Ivan and Mr. Mui Pak Kuen.

The unaudited condensed consolidated financial statements of the Company for the three and nine months ended 31 December 2018 has been reviewed by the Audit Committee. The Audit Committee is of the opinion that such financial information complies with the applicable accounting standards, the GEM Listing Rules and legal requirements, and that adequate disclosure have been made.

By order of the Board

Prime Intelligence Solutions Group Limited 匯安智能科技集團有限公司 Mr. Yuen Kwok Wai, Tony Chairman

Hong Kong, 4 February 2019

As at the date of this report, the executive Directors are Mr. Yuen Kwok Wai, Tony, Ms. Yuen Mei Ling, Pauline, and Ms. Sun Ngai Chu, Danielle; the non-executive Director is Mr. Yam Chiu Fan, Joseph; and the independent non-executive Directors are Mr. Hui Man Ho, Ivan, Mr. Chung Billy and Mr. Mui Pak Kuen.

#### 審核委員會

本公司已遵循GEM上市規則第5.28及5.29條及企業管治守則條文第C.3.3及C.3.7條成立審核委員會,並以書面列明其職權範疇。審核委員會的主要職責為檢討及監察本集團的財務申報程序及內部監控系統。審核委員會由三名獨立非執行董事組成,即鍾定縉先生(審核委員會主席)、許文浩先生及梅柘權先生。

本公司截至2018年12月31日止三個月及九個月的未經審核簡明綜合財務報表已經審核委員會審閱。審核委員會認為,有關財務資料符合適用會計準則、GEM上市規則及法定要求,並已作出足夠披露。

承董事會命

Prime Intelligence Solutions Group Limited 匯安智能科技集團有限公司

主席

阮國偉先生

香港,2019年2月4日

於本報告日期,執行董事為阮國偉先生、阮美玲女士及孫毅 珠女士: 非執行董事為任超凡先生: 及獨立非執行董事為許 文浩先生、鍾定縉先生及梅栢權先生。

#